The Gavi Leap tracker
Get the latest updates and view the progress made as part of global health's most ambitious reform programmes.
Leaving no one behind with immunisation
Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate more than half the world’s children against some of the world's deadliest diseases.
About us Explore our Progress Report
Latest VaccinesWork features
View moreLiving with chronic hepatitis B in Kenya
More than 10% of the people living in Migori County’s fishing communities are infected with hepatitis B, a vaccine-preventable virus that can cause liver failure and cancer.
Nigeria faces the world’s highest projected death toll from super El Niño heat
The super El Niño could cause 31,400 extra heat deaths in Nigeria alone. Heat warnings, cooling centres and worker protections could help save lives.
Why do some people get worse vaccine side-effects than others?
New research highlights the role of the innate immune system in triggering temporary side-effects such as fever, fatigue, headache and injection site pain following vaccination.
VaccinesWork is an award-winning digital platform hosted by Gavi, covering news, features and explainers from every corner of global health and immunisation.
The Gavi Leap
The Gavi Leap
The Gavi Leap is the most ambitious reform agenda in global health, offering a blueprint for broader reform of the health and development architecture. Learn more about how Leap principles, such as country ownership, radical simplification and innovation, are already having a tangible impact on how immunisation is delivered in Gavi-supported countries.
Our work
Vaccine portfolio
Gavi supports vaccines against 20 infectious diseases, including Ebola, malaria, mpox and rabies.
Health systems support
Strong health and immunisation systems are vital to deliver vaccines to all the children who need them.
Latest Gavi news releases
View all
New “blockbuster” tuberculosis vaccines could save seven million lives by 2050
Next-generation TB vaccines, expected to become available from 2029, could deliver major health and economic gains, helping to save an estimated 7.3 million lives, generate up to US$ 135 billion in economic benefits for low-and middle-income…
Gavi welcomes prequalification of multi-dose RSV maternal vaccine to protect infants
WHO prequalification of a multi-dose RSV maternal vaccine marks a major step towards protecting newborns and infants from one of the leading causes of severe respiratory illness, hospitalisation and death worldwide.
The Vaccine Alliance
The Vaccine Alliance
Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.
Gavi 6.0 funding guidelines
Newly released funding guidelines outline the scope of Gavi’s vaccine and cash support for the 2026–2030 strategic period (Gavi 6.0), explain how countries should plan and prioritise their immunisation programmes within this support, clarify the requirements for the Gavi 6.0 country application and describe how to access other forms of assistance such as outbreak and emergency support.
Partner countries
Partner countries
Since its inception in 2000, Gavi has helped to immunise a whole generation – over 1.2 billion children – and prevented more than 20.6 million future deaths, helping to halve child mortality in 78 lower‑income countries.
Our donors
Our donors
As a public-private partnership, Gavi is funded by governments, foundations, institutions, organisations, corporations and private individuals.
